Email: cspc@cspc.cn
News
News Center
Nov. 04
2023
VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 02
VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Oct. 31
CSPC's DP303c Research Findings Presented at ESMO
150 Party Organization Secretaries Visit CSPC
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL
Oct. 30
CSPC's GLP-1 Targeted Drug Project Approved as a Major Technology Innovation Project
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
